Correlations between leukocyte TL and hippocampal volume among <i>APOE</i> ε3/ε3 and <i>APOE</i> ε4 carriers.

<p>Leukocyte TL was adjusted for age. Hippocampal volume was adjusted for body (and head) size and age. Regression lines only shown for significant Spearman correlations.</p

General characteristics of study participants.

<p>All values are means unless otherwise stated. MMSE, Mini-mental state examination; SD, standard deviation.</p>a<p>Blood pressure ≥140/90 or taking antihypertensive medication.</p>b<p>Adjusted for body (and head) size and age.</p>c<p>Adjusted for age.</p

Additional file 2: Supplementary figures. of Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains

(DOC 2024 kb

Additional file 1: Supplementary tables. of Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains

(DOC 1000 kb

Additional file 3: of The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Table S3. Biomarker protocol information for each cohort. Protocol information for PET, CSF and plasma biomarker collection (DOCX 100 kb

Additional file 4: of The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Table S4. Ethical approval committee of each center. Ethical approval committees in each of the participating centers (DOCX 109 kb

Additional file 1: of The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Table S1. Diagnostic criteria per cohort. Cohorts, countries, number of subjects and diagnostic criteria used for NC, MCI and AD dementia (DOCX 90 kb

New genome-wide significant genes associated with AD in the vicinity of recently reported single SNP genome-wide significant hits[9], [19].

<p>Gene-wide p-values are shown for those genes with p<2.5×10⁻⁶ for which the best single-SNP p-value in that gene is greater than 5×10⁻⁸ in the combined Stage 1 and Stage 2 sample. Previously reported genes<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094661#pone.0094661-Harold1" target="_blank">[4]</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094661#pone.0094661-Seshadri1" target="_blank">[8]</a> ± 0.5 Mb around them are excluded.</p><p>Gene-wide p-values in the combined Stage 1 and Stage 2 sample obtained by combining the p-values from the Stage 1 with those from the Stage 2 using Fisher's method. The LD between rs1476679 (chr7∶100,004,446) reported by IGAP <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094661#pone.0094661-Lambert2" target="_blank">[9]</a> and the best SNP in ZNF3 is r² = 0.16. The LD between rs10838725 (chr11: 47,557,871) reported by IGAP <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094661#pone.0094661-Lambert2" target="_blank">[9]</a> and the best SNPs in the region on chr 11 in the table are r² = 0.3 and 0.88 for <i>NDUFS3</i> and <i>MTCH2</i> respectively.</p

Overrepresentation of significant loci, excluding regions of 0.5[4]–[8] and Stage 1 IGAP genes[9], [19] containing genome-wide significant SNPs.

<p>The observed number of genes is calculated by combining significant loci within 0.5 Mb into one signal. The APOE region is excluded (CHR19; 44,411,940–46,411,945bp). The total number of genes after exclusions is 24,849.</p

New genome-wide significant genes associated with AD.

<p>Gene-wide p-values are shown for those genes with p<2.5×10⁻⁶ for which the best single-SNP p-value in that gene is greater than 5×10⁻⁸ in the combined Stage 1 and Stage 2 sample. Previously reported genes<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094661#pone.0094661-Harold1" target="_blank">[4]</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094661#pone.0094661-Seshadri1" target="_blank">[8]</a> ± 0.5 Mb around them are excluded.</p><p>Gene-wide p-values in the combined Stage 1 and Stage 2 sample obtained by combining the p-values from the Stage 1 with those from the Stage 2 using Fisher's method.</p